Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor Channels

Serge Guerreiro, Damien Toulorge, Etienne Hirsch, Marc Marien, Pierre Sokoloff and Patrick P. Michel
Molecular Pharmacology October 2008, 74 (4) 980-989; DOI: https://doi.org/10.1124/mol.108.048207
Serge Guerreiro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damien Toulorge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etienne Hirsch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Marien
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Sokoloff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick P. Michel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 74 no. 4 980-989
DOI 
https://doi.org/10.1124/mol.108.048207
PubMed 
18621927

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received April 24, 2008
  • Accepted July 11, 2008
  • Published online September 18, 2008.

Article Versions

  • Earlier version (July 11, 2008 - 09:43).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Serge Guerreiro,
  2. Damien Toulorge,
  3. Etienne Hirsch,
  4. Marc Marien,
  5. Pierre Sokoloff and
  6. Patrick P. Michel
  1. Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S679, Experimental Neurology and Therapeutics, Paris, France (S.G., D.T., E.H., P.P.M.); Université Pierre et Marie Curie-Paris 6, Paris, France (S.G., D.T., E.H., P.P.M.); and Centre de Recherche Pierre Fabre, Castres, France (M.M., P.S., P.P.M.)
  1. Address correspondence to:
    Dr. Patrick P. Michel, Unité Mixte de Recherche Institut National de la Santé et de la Recherche Médicale/Université Pierre et Marie Curie-Paris-6, Bât. Pharmacie, Hôpital de la Salpêtrière, 47, bd de l'hôpital, 75013 Paris, France. E-mail: patrick-pierre.michel{at}upmc.fr
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: July 2008 to August 2022

AbstractFullPdf
Jul 200854081
Aug 200844054
Sep 200893790
Oct 20081063134
Nov 20081263629
Dec 2008541218
Jan 2009372615
Feb 2009351111
Mar 2009291324
Apr 2009242235
May 200915810
Jun 2009161312
Jul 2009261122
Aug 20092889
Sep 200918612
Oct 2009223331
Nov 2009173136
Dec 2009171214
Jan 2010323345
Feb 2010233423
Mar 2010233321
Apr 2010113117
May 201023348
Jun 2010283027
Jul 2010202516
Aug 2010197524
Sep 2010223526
Oct 201093221
Nov 2010315929
Dec 2010171818
Jan 2011372027
Feb 2011217620
Mar 2011319235
Apr 2011294233
May 2011183727
Jun 2011122523
Jul 2011232326
Aug 2011192533
Sep 2011347229
Oct 2011275524
Nov 2011307426
Dec 2011262922
Jan 2012226932
Feb 2012236630
Mar 2012258449
Apr 2012247837
May 2012265427
Jun 2012233735
Jul 2012224640
Aug 2012214026
Sep 2012325936
Oct 2012286334
Nov 2012285426
Dec 2012272322
Jan 2013286734
Feb 2013287734
Mar 2013284524
Apr 2013265725
May 2013298041
Jun 201320419
Jul 2013163214
Aug 2013103910
Sep 2013274814
Oct 2013214518
Nov 201329336
Dec 2013153815
Jan 2014363428
Feb 2014112917
Mar 2014205720
Apr 2014257820
May 2014195421
Jun 2014124813
Jul 2014205512
Aug 201416509
Sep 201466423
Oct 2014146411
Nov 2014286114
Dec 2014177624
Jan 2015145916
Feb 201594723
Mar 2015187216
Apr 2015166412
May 2015235615
Jun 201594612
Jul 2015145213
Aug 201514426
Sep 201514514
Oct 201523666
Nov 201519347
Dec 20155448
Jan 2016159011
Feb 201611428
Mar 2016166819
Apr 201615778
May 2016156814
Jun 2016186016
Jul 2016223923
Aug 2016135720
Sep 201688813
Oct 2016611420
Nov 2016109910
Dec 20163825
Jan 20172919
Feb 201701025
Mar 201729511
Apr 20173856
May 20172427
Jun 20171634
Jul 20172428
Aug 20171552
Sep 20172454
Oct 201745211
Nov 201755510
Dec 20173454
Jan 201854715
Feb 20184517
Mar 201863510
Apr 201825918
May 201876810
Jun 20180608
Jul 20180477
Aug 201804919
Sep 20180439
Oct 201815315
Nov 20181687
Dec 201858309
Jan 201936711
Feb 20194859
Mar 20194625
Apr 20195632
May 20193825
Jun 201936814
Jul 20195012
Aug 2019481058
Sep 201947604
Oct 20196967
Nov 20196053
Dec 20194443
Jan 20206033
Feb 20204430
Mar 20202920
Apr 20204403
May 20201710
Jun 20201710
Jul 20202630
Aug 20201901
Sep 20203140
Oct 20204032
Nov 20204831
Dec 20206163
Jan 20213864
Feb 20215243
Mar 20215843
Apr 202137133
May 20213173
Jun 20213152
Jul 20213245
Aug 20214371
Sep 20214961
Oct 20215264
Nov 20216914
Dec 20214142
Jan 20224430
Feb 20223523
Mar 20225423
Apr 20223742
May 20224132
Jun 20223551
Jul 20223312
Aug 20221611

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 74 (4)
Molecular Pharmacology
Vol. 74, Issue 4
1 Oct 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor Channels
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor Channels

Serge Guerreiro, Damien Toulorge, Etienne Hirsch, Marc Marien, Pierre Sokoloff and Patrick P. Michel
Molecular Pharmacology October 1, 2008, 74 (4) 980-989; DOI: https://doi.org/10.1124/mol.108.048207

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor Channels

Serge Guerreiro, Damien Toulorge, Etienne Hirsch, Marc Marien, Pierre Sokoloff and Patrick P. Michel
Molecular Pharmacology October 1, 2008, 74 (4) 980-989; DOI: https://doi.org/10.1124/mol.108.048207
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Anti-aromatase activity of exemestane phase II metabolites
  • α-Conotoxin Binding Site on the GABAB Receptor
  • Upacicalcet binds to the amino acid binding site of CaSR
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics